Trial reportCancer discovery2018
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1
Open access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 282 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
282citing papers in PubMed, 1 pooled it
16.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
282 citing papers in PubMed, 1 synthesis or guideline pooled it, 419 citations in OpenAlex.
- Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis.Cancer immunology, immunotherapy : CII · 2023Pooled it
- CMV-specific T-cell receptor-engineered T-cell therapy as first-line treatment for CMV reactivation after haploidentical hematopoietic stem cell transplantation: a phase 2 trial.Frontiers in immunology · 2026Trial
- Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.Lancet (London, England) · 2024Trial
- Trial
- Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.BMC cancer · 2023Trial
- Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Trial
- The promise of immunotherapy in the treatment of sarcoma: A state-of-the-art review of practice changing research and future directions.Human vaccines & immunotherapeutics · 2026Review
- The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions.Human vaccines & immunotherapeutics · 2026Review
- T cell receptors equipped with ICOS provide T cells with durable anti-tumor response.Molecular cancer · 2026Article
- Cell-based cancer immunotherapy: milestones, mechanistic insights, and emerging therapeutic directions.Acta pharmacologica Sinica · 2026Review
- Leveraging multimodal cancer immunotherapy to amplify the efficacy of oncolytic viruses.Experimental hematology & oncology · 2026Review
- Hallmarks and correlates of effective adoptive cell immunotherapy for cancer.Nature reviews. Immunology · 2026Review
- Sarcomas in Adolescents and Young Adults.Current oncology reports · 2026Review
- Progress in cell-based immunotherapies for solid tumors.Discover oncology · 2026Review
- Cell therapy in sarcoma: current landscape and future directions.Journal for immunotherapy of cancer · 2026Review
- Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activityFrontiers in immunology · 2026Article
- T cell immunotherapy for solid tumors: limitations, progress, and future prospects.Frontiers in immunology · 2026Review
222 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors at 5 institutions in 2 countries.
Sandra P D'Angelo *Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York. E-mail:dangelos@mskcc.org.
Luca Melchiori *Adaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Melinda S MerchantPediatric Oncology Branch, NCI, Bethesda, Maryland.
Donna BernsteinPediatric Oncology Branch, NCI, Bethesda, Maryland.
John GlodPediatric Oncology Branch, NCI, Bethesda, Maryland.
Rosandra KaplanPediatric Oncology Branch, NCI, Bethesda, Maryland.
Stephan GruppChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania.
William D TapMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Karen ChaginAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Gwendolyn K BinderAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Samik BasuAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Daniel E LowtherAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Ruoxi WangAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Natalie BathAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Alex TippingAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Gareth BettsAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Indu RamachandranAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Jean-Marc NavenotAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Hua ZhangPediatric Oncology Branch, NCI, Bethesda, Maryland.
Daniel K WellsParker Institute for Cancer Immunotherapy, San Francisco, California.
Erin Van WinkleAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Gabor KariAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Trupti TrivediAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Tom HoldichAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Lini PanditeAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Rafael AmadoAdaptimmune, Oxford, United Kingdom, and Philadelphia, Pennsylvania.
Crystal L MackallPediatric Oncology Branch, NCI, Bethesda, Maryland.ORCID 0000-0003-0359-9023
Adaptimmune (United Kingdom) · GBMaryland Oncology Hematology · USMemorial Sloan Kettering Cancer Center · USChildren's Hospital of Philadelphia · USParker Institute for Cancer Immunotherapy · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MPediatric Oncology Branch Clinical Care and EducationZIEBC011516 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GLOD, JOHN · 2013 to 2025
$69.1MTargeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI William D. Tap · 2018 to 2026
$21.5MTumor Microenvironment in Cancer ProgressionZIABC011332 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KAPLAN, ROSANDRA NATASHA · 2010 to 2025
$10.8MIntramural NIH HHS ZIA BC011332NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA217694
Abstract
We evaluated the safety and activity of autologous T cells expressing NY-ESO-1
Indexed as
Adoptive TransferAdultAntigens, NeoplasmCD8-Positive T-LymphocytesFemaleHumansMaleMembrane ProteinsMiddle AgedNeoplasm MetastasisPilot ProjectsReceptors, Antigen, T-CellSarcoma, SynovialT-LymphocytesTreatment OutcomeYoung AdultAntigens, NeoplasmCTAG1B protein, humanMembrane ProteinsReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.